{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:31:07Z","timestamp":1793241067640,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of biomarkers linked to clinical remission in RA is currently a challenge. Metabolomics may help to identify such biomarkers as it allows for a comprehensive exploration of disease-related variations that extends beyond the genome and proteome. This hypothesis-free exploratory metabolomics study aimed to profile serum metabolic alterations in early RA to understand the metabolic changes associated with disease activity and therapeutic response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study included 220 early RA participants from the NORD-STAR study, randomized at baseline into four arms, ranging from conventional anti-rheumatic treatment to biological drugs: methotrexate combined with prednisolone (1), certolizumab (2), abatacept (3), or tocilizumab (4). Untargeted metabolomics was performed in serum samples at baseline and 24-week follow-up. Participants achieving clinical disease activity index remission at 24 weeks were defined as responders. Machine learning models for treatment response were constructed using random forest, logistic regression, support vector machine and extreme gradient boosting algorithms based on selected features.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 278 metabolites, of which 39 were associated with baseline disease activity, including several acylcarnitines and amino acids. We also found 17 baseline metabolites associated with remission at 24 weeks in the overall cohort, including malic acid (\u03b2=-0.4), cytidine (\u03b2\u2009=\u20090.4), arginine (\u03b2\u2009=\u20090.3), and citrulline (\u03b2\u2009=\u20090.2), as well as specific metabolites and metabolic pathways associated with remission in the four treatment arms. Fifteen features were identified using machine learning-based multivariable selection. The best predictive model using logistic regression achieved AUC of 0.75 in training and 0.73 in the test set.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study has identified several baseline metabolites and metabolic pathways associated with disease activity and response to different treatments in early RA. By integrating metabolomics and clinical data, we developed predictive models for response to treatment in early RA, though their predictive performance remains limited.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13075-025-03616-6","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:28:55Z","timestamp":1753511335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort"],"prefix":"10.1186","volume":"27","author":[{"given":"Tahzeeb","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Vasileiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Rawshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Gr\u00f6ndal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte S.","family":"Heiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Maglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"3616_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"J Smolen","year":"2018","unstructured":"Smolen J, Aletaha D, Barton A, Burmester G, Emery P, Firestein G. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"3616_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863\u201377.","journal-title":"Rheumatol Int"},{"issue":"6","key":"3616_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Van Vollenhoven RF, De Wit M. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"3616_CR4","doi-asserted-by":"crossref","unstructured":"Hetland ML, Haavardsholm EA, Rudin A, Nordstr\u00f6m D, Nurmohamed M, Gudbjornsson B, Lampa J, H\u00f8rslev-Petersen K, Uhlig T, Grondal G. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:m4328.","DOI":"10.1136\/bmj.m4328"},{"issue":"10","key":"3616_CR5","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591\u2013602.","journal-title":"Nat Rev Rheumatol"},{"key":"3616_CR6","doi-asserted-by":"publisher","first-page":"1049875","DOI":"10.3389\/fmed.2022.1049875","volume":"9","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, Hashimoto M. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med. 2022;9:1049875.","journal-title":"Front Med"},{"key":"3616_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-016-1094-6","volume":"12","author":"RD Beger","year":"2016","unstructured":"Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T. Metabolomics enables precision medicine:a white paper, community perspective. Metabolomics. 2016;12:1\u201315.","journal-title":"Metabolomics"},{"key":"3616_CR8","unstructured":"Rootwelt H, Elgst\u00f8en KBP. Metabolomics\u2013a new biochemical golden age for personalised medicine. Tidsskrift Den Norske Legeforening 2022:142."},{"issue":"9","key":"3616_CR9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/art.41733","volume":"73","author":"X Shen","year":"2021","unstructured":"Shen X, Wang C, Liang N, Liu Z, Li X, Zhu ZJ, Merriman TR, Dalbeth N, Terkeltaub R, Li C. Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol. 2021;73(9):1738\u201348.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3616_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","volume":"28","author":"T Buergel","year":"2022","unstructured":"Buergel T, Steinfeldt J, Ruyoga G, Pietzner M, Bizzarri D, Vojinovic D, Upmeier zu Belzen J, Loock L, Kittner P, Christmann L. Metabolomic profiles predict individual multidisease outcomes. Nat Med. 2022;28(11):2309\u201320.","journal-title":"Nat Med"},{"issue":"1","key":"3616_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-021-03169-7","volume":"19","author":"H Luan","year":"2021","unstructured":"Luan H, Gu W, Li H, Wang Z, Lu L, Ke M, Lu J, Chen W, Lan Z, Xiao Y. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. J Translational Med. 2021;19(1):1\u201310.","journal-title":"J Translational Med"},{"issue":"4","key":"3616_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11306-023-02004-y","volume":"19","author":"M Cedeno","year":"2023","unstructured":"Cedeno M, Murillo-Saich J, Coras R, Cedola F, Brandy A, Prior A, Pedersen A, Mateo L, Martinez-Morillo M, Guma M. Serum metabolomic profiling identifies potential biomarkers in arthritis in older adults: an exploratory study. Metabolomics. 2023;19(4):37.","journal-title":"Metabolomics"},{"issue":"9","key":"3616_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11306-021-01822-2","volume":"17","author":"JD Murillo-Saich","year":"2021","unstructured":"Murillo-Saich JD, Diaz-Torne C, Ortiz MA, Coras R, Gil-Alabarse P, Pedersen A, Corominas H, Vidal S, Guma M. Metabolomics profiling predicts outcome of Tocilizumab in rheumatoid arthritis: an exploratory study. Metabolomics. 2021;17(9):74.","journal-title":"Metabolomics"},{"issue":"12","key":"3616_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/metabo11120824","volume":"11","author":"MR Medcalf","year":"2021","unstructured":"Medcalf MR, Bhadbhade P, Mikuls TR, O\u2019dell JR, Gundry RL, Funk RS. Plasma metabolome normalization in rheumatoid arthritis following initiation of methotrexate and the identification of metabolic biomarkers of efficacy. Metabolites. 2021;11(12):824.","journal-title":"Metabolites"},{"issue":"4","key":"3616_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/diseases11040164","volume":"11","author":"K Mac\u00e1kov\u00e1","year":"2023","unstructured":"Mac\u00e1kov\u00e1 K, Teke\u013eov\u00e1 M, Mlyn\u00e1rikov\u00e1 V, \u0160ebekov\u00e1 K, Vlkov\u00e1 B, Celec P, \u0160te\u0148ov\u00e1 E. Metabolic effects of Anti-TNF-\u03b1 treatment in rheumatoid arthritis. Diseases. 2023;11(4):164.","journal-title":"Diseases"},{"issue":"7","key":"3616_CR16","doi-asserted-by":"publisher","first-page":"e0219400","DOI":"10.1371\/journal.pone.0219400","volume":"14","author":"C Sasaki","year":"2019","unstructured":"Sasaki C, Hiraishi T, Oku T, Okuma K, Suzumura K, Hashimoto M, Ito H, Aramori I, Hirayama Y. Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis. PLoS ONE. 2019;14(7):e0219400.","journal-title":"PLoS ONE"},{"issue":"8","key":"3616_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.38021","volume":"65","author":"SP Young","year":"2013","unstructured":"Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, Kitas GD, Raza K. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthr Rhuem. 2013;65(8):2015\u201323.","journal-title":"Arthr Rhuem"},{"key":"3616_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1729-2","volume":"20","author":"XM Teitsma","year":"2018","unstructured":"Teitsma XM, Yang W, Jacobs JW, Peth\u00f6-Schramm A, Borm ME, Harms AC, Hankemeier T, van Laar JM, Bijlsma JW, Lafeber FP. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res Therapy. 2018;20:1\u201311.","journal-title":"Arthritis Res Therapy"},{"key":"3616_CR19","doi-asserted-by":"publisher","first-page":"676105","DOI":"10.3389\/fimmu.2021.676105","volume":"12","author":"GS Jutley","year":"2021","unstructured":"Jutley GS, Sahota K, Sahbudin I, Filer A, Arayssi T, Young SP, Raza K. Relationship between inflammation and metabolism in patients with newly presenting rheumatoid arthritis. Front Immunol. 2021;12:676105.","journal-title":"Front Immunol"},{"issue":"10","key":"3616_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M \u00d8stergaard","year":"2023","unstructured":"\u00d8stergaard M, Van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordstr\u00f6m DC, Nurmohamed MT, Gudbjornsson B, \u00d8rnbjerg LM, B\u00f8yesen P. Certolizumab pegol, abatacept, Tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023;82(10):1286\u201395.","journal-title":"Ann Rheum Dis"},{"key":"3616_CR21","doi-asserted-by":"crossref","unstructured":"Xia J, Wishart DS. Metabolomic data processing, analysis, and interpretation using MetaboAnalyst. Current protocols in bioinformatics 2011;34(1):14\u201310.","DOI":"10.1002\/0471250953.bi1410s34"},{"key":"3616_CR22","unstructured":"Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2021. https:\/\/www.R-project.org\/"},{"issue":"1","key":"3616_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1039\/C4MB00414K","volume":"11","author":"MN Triba","year":"2015","unstructured":"Triba MN, Le Moyec L, Amathieu R, Goossens C, Bouchemal N, Nahon P, Rutledge DN, Savarin P. PLS\/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol Biosyst. 2015;11(1):13\u20139.","journal-title":"Mol Biosyst"},{"issue":"1\u20132","key":"3616_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.chemolab.2004.12.011","volume":"78","author":"I-G Chong","year":"2005","unstructured":"Chong I-G, Jun C-H. Performance of some variable selection methods when multicollinearity is present. Chemometr Intell Lab Syst. 2005;78(1\u20132):103\u201312.","journal-title":"Chemometr Intell Lab Syst"},{"issue":"1","key":"3616_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-338","volume":"14","author":"G Nyamundanda","year":"2013","unstructured":"Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics. 2013;14(1):1\u20138.","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"3616_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/bioinformatics\/bty710","volume":"35","author":"L Shi","year":"2019","unstructured":"Shi L, Westerhuis JA, Ros\u00e9n J, Landberg R, Brunius C. Variable selection and validation in multivariate modelling. Bioinformatics. 2019;35(6):972\u201380.","journal-title":"Bioinformatics"},{"issue":"3","key":"3616_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/pharmrev.121.000408","volume":"74","author":"M Dambrova","year":"2022","unstructured":"Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, Smesny S, Sen ZD, Guo AC, Oler E. Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. Pharmacol Rev. 2022;74(3):506\u201351.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3616_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-021-02537-4","volume":"23","author":"B Hur","year":"2021","unstructured":"Hur B, Gupta VK, Huang H, Wright KA, Warrington KJ, Taneja V, Davis JM III, Sung J. Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity. Arthritis Res Therapy. 2021;23(1):164.","journal-title":"Arthritis Res Therapy"},{"key":"3616_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1215-7","volume":"19","author":"KM Huffman","year":"2017","unstructured":"Huffman KM, Jessee R, Andonian B, Davis BN, Narowski R, Huebner JL, Kraus VB, McCracken J, Gilmore BF, Tune KN. Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability. Arthritis Res Therapy. 2017;19:1\u201317.","journal-title":"Arthritis Res Therapy"},{"issue":"11","key":"3616_CR30","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1093\/rheumatology\/keaa125","volume":"59","author":"SH Chu","year":"2020","unstructured":"Chu SH, Cui J, Sparks JA, Lu B, Tedeschi SK, Speyer CB, Moss L, Feser ML, Kelmenson LB, Mewshaw EA. Circulating plasma metabolites and risk of rheumatoid arthritis in the nurses\u2019 health study. Rheumatology. 2020;59(11):3369\u201379.","journal-title":"Rheumatology"},{"key":"3616_CR31","doi-asserted-by":"publisher","first-page":"102974","DOI":"10.1016\/j.jaut.2022.102974","volume":"134","author":"T de Jong","year":"2023","unstructured":"de Jong T, Semmelink J, Denis S, van de Sande M, Houtkooper R, van Baarsen L. Altered lipid metabolism in synovial fibroblasts of individuals at risk of developing rheumatoid arthritis. J Autoimmun. 2023;134:102974.","journal-title":"J Autoimmun"},{"issue":"2","key":"3616_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","volume":"28","author":"A Frances","year":"2020","unstructured":"Frances A, Cordelier P. The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy? Mol Ther. 2020;28(2):357\u201366.","journal-title":"Mol Ther"},{"issue":"1","key":"3616_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/ard.45.1.9","volume":"45","author":"P Thompson","year":"1986","unstructured":"Thompson P, Jones D, Currey H. Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis. Ann Rheum Dis. 1986;45(1):9.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3616_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1365-3083.2009.02302.x","volume":"70","author":"X Xu","year":"2009","unstructured":"Xu X, Hsu HC, Chen J, Grizzle WE, Chatham WW, Stockard CR, Wu Q, Yang P, Holers VM, Mountz JD. Increased expression of activation-induced cytidine deaminase is associated with anti\u2010CCP and rheumatoid factor in rheumatoid arthritis. Scand J Immunol. 2009;70(3):309\u201316.","journal-title":"Scand J Immunol"},{"issue":"D1","key":"3616_CR35","doi-asserted-by":"publisher","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","volume":"50","author":"DS Wishart","year":"2022","unstructured":"Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res. 2022;50(D1):D622\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"3616_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0968-0004(79)90417-1","volume":"4","author":"A Dawson","year":"1979","unstructured":"Dawson A. Oxidation of cytosolic NADH formed during aerobic metabolism in mammalian cells. Trends Biochem Sci. 1979;4(8):171\u20136.","journal-title":"Trends Biochem Sci"},{"issue":"12","key":"3616_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-021-01065-2","volume":"22","author":"B Wu","year":"2021","unstructured":"Wu B, Zhao TV, Jin K, Hu Z, Abdel MP, Warrington KJ, Goronzy JJ, Weyand CM. Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nat Immunol. 2021;22(12):1551\u201362.","journal-title":"Nat Immunol"},{"issue":"12","key":"3616_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1136\/gut.2004.042317","volume":"53","author":"S Osowska","year":"2004","unstructured":"Osowska S, Moinard C, Lo\u00ef C, Neveux N, Cynober L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut. 2004;53(12):1781.","journal-title":"Gut"},{"key":"3616_CR39","doi-asserted-by":"crossref","unstructured":"Makrygiannakis D, af Klint E, Lundberg IE, L\u00f6fberg R, Ulfgren AK, Klareskog L, Catrina AI. Citrullination is an inflammation dependent process. Annals of the rheumatic diseases 2006;65:1219\u20131222.","DOI":"10.1136\/ard.2005.049403"},{"key":"3616_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4439","volume":"16","author":"SD Seegobin","year":"2014","unstructured":"Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, Scott IC. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Therapy. 2014;16:1\u201312.","journal-title":"Arthritis Res Therapy"},{"issue":"7","key":"3616_CR41","first-page":"358","volume":"17","author":"L-W Huang","year":"2001","unstructured":"Huang L-W, Chang K-L, Chen C-J, Liu H-W. Arginase levels are increased in patients with rheumatoid arthritis. Kaohsiung J Med Sci. 2001;17(7):358\u201363.","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"3616_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/ard-2022-223626","volume":"83","author":"S Cao","year":"2024","unstructured":"Cao S, Li Y, Song R, Meng X, Fuchs M, Liang C, Kachler K, Meng X, Wen J, Schl\u00f6tzer-Schrehardt U. L-arginine metabolism inhibits arthritis and inflammatory bone loss. Ann Rheum Dis. 2024;83(1):72\u201387.","journal-title":"Ann Rheum Dis"},{"key":"3616_CR43","doi-asserted-by":"crossref","unstructured":"Bartikoski BJ, De Oliveira MS, do, Esp\u00edrito Santo RC, Dos Santos LP, Dos Santos NG, Xavier RM. A review of metabolomic profiling in rheumatoid arthritis: bringing new insights in disease pathogenesis, treatment and comorbidities. Metabolites. 2022;12(5):394.","DOI":"10.3390\/metabo12050394"},{"key":"3616_CR44","doi-asserted-by":"publisher","first-page":"961708","DOI":"10.3389\/fimmu.2022.961708","volume":"13","author":"L Xu","year":"2022","unstructured":"Xu L, Chang C, Jiang P, Wei K, Zhang R, Jin Y, Zhao J, Xu L, Shi Y, Guo S. Metabolomics in rheumatoid arthritis: advances and review. Front Immunol. 2022;13:961708.","journal-title":"Front Immunol"},{"issue":"11","key":"3616_CR45","doi-asserted-by":"publisher","first-page":"e0138537","DOI":"10.1371\/journal.pone.0138537","volume":"10","author":"R Priori","year":"2015","unstructured":"Priori R, Casadei L, Valerio M, Scrivo R, Valesini G, Manetti C. 1H-NMR-based metabolomic study for identifying serum profiles associated with the response to etanercept in patients with rheumatoid arthritis. PLoS ONE. 2015;10(11):e0138537.","journal-title":"PLoS ONE"},{"issue":"1","key":"3616_CR46","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.1038\/s41598-021-86729-7","volume":"11","author":"M Maciejewski","year":"2021","unstructured":"Maciejewski M, Sands C, Nair N, Ling S, Verstappen S, Hyrich K, Barton A, Ziemek D, Lewis MR, Plant D. Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. Sci Rep. 2021;11(1):7266.","journal-title":"Sci Rep"},{"issue":"1","key":"3616_CR47","doi-asserted-by":"publisher","first-page":"15286","DOI":"10.1038\/s41598-019-51258-x","volume":"9","author":"L Lello","year":"2019","unstructured":"Lello L, Raben TG, Yong SY, Tellier LC, Hsu SD. Genomic prediction of 16 complex disease risks including heart attack, diabetes, breast and prostate cancer. Sci Rep. 2019;9(1):15286.","journal-title":"Sci Rep"},{"issue":"7","key":"3616_CR48","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/genes12070991","volume":"12","author":"E Widen","year":"2021","unstructured":"Widen E, Raben TG, Lello L, Hsu SD. Machine learning prediction of biomarkers from SNPs and of disease risk from biomarkers in the UK biobank. Genes. 2021;12(7):991.","journal-title":"Genes"}],"updated-by":[{"DOI":"10.1186\/s13075-025-03657-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03616-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:04:40Z","timestamp":1758870280000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3616"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03616-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors reported a typesetting error. Table footnote for tables 1 and 2 were misplace in the main text.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13075-025-03657-x","URL":"https:\/\/doi.org\/10.1186\/s13075-025-03657-x","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the regional ethics board in Stockholm with ethical approval number 2011\/2069-31\/4 (amendment numbers: 2020\u201303797).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients and\/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research. Patient consent for publication is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}